Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Down 37.3% in May

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totaling 67,479 shares, a drop of 37.3% from the April 30th total of 107,543 shares. Based on an average trading volume of 156,723 shares, the short-interest ratio is presently 0.4 days. Approximately 18.5% of the company’s shares are short sold.

Analyst Ratings Changes

A number of equities analysts have recently commented on JAGX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Jaguar Animal Health Price Performance

JAGX opened at $3.05 on Friday. The company has a fifty day simple moving average of $8.51 and a 200 day simple moving average of $23.24. The firm has a market cap of $1.84 million, a price-to-earnings ratio of -0.01 and a beta of -0.09. Jaguar Animal Health has a twelve month low of $2.53 and a twelve month high of $144.55. The company has a current ratio of 0.50, a quick ratio of 0.30 and a debt-to-equity ratio of 4.08.

Jaguar Animal Health (NASDAQ:JAGX) last released its quarterly earnings results on Wednesday, May 20th. The biotechnology company reported ($13.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($149.10) by $135.50. The business had revenue of $20.27 million during the quarter, compared to analyst estimates of $4.21 million. Jaguar Animal Health had a negative net margin of 169.04% and a negative return on equity of 1,194.94%.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.